GlassScriptPhysician profile
Steven A Sandler
NPI 1326129792
$14,430.04
in general payments reported to CMS, 2019-2025
45 companies · $695 in 2025
The $695 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,024 · 2020: $1,276 · 2021: $1,909 · 2022: $4,382 · 2024: $1,144 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.89 |
| Education | $219.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,470.88 | 2019-2022 | |
| Celgene Corporation | $3,286.11 | 2019-2024 | Pomalyst |
| Amgen INC. | $852.14 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $805.84 | 2019-2024 | |
| Janssen Biotech, INC. | $708.79 | 2019-2024 | Imbruvica, Talvey, Tecvayli |
| Incyte Corporation | $593.21 | 2019-2025 | Jakafi |
| Genzyme Corporation | $464.62 | 2019-2025 | |
| Pfizer INC. | $400.04 | 2019-2025 | |
| Seagen INC. | $399.29 | 2019-2022 | |
| Genentech USA, INC. | $272.32 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $266.37 | 2019-2025 | Opdivo |
| Gilead Sciences, INC. | $231.30 | 2021-2025 | Trodelvy |
| Exelixis INC. | $212.66 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $206.55 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $205.11 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.